person · Reporting owner
Silverstein Christine Berni
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABEONA THERAPEUTICS INC.
Report date June 15, 2026 · Filed June 15, 2026
Section 16 reporting ended · disclosed 2026-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 119,562 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Sale · Disposed 18,160 · Balance 119,562 F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.73 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.73 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
MARINUS PHARMACEUTICALS, INC.
Report date February 07, 2025 · Filed February 11, 2025
Section 16 reporting ended · disclosed 2025-02-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-02-07 · Disposition to issuer · Disposed 9,398 · Balance 4,702 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Row 2 · 2025-02-11 · Disposition to issuer · Disposed 4,702 · Balance 0 F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2: Represents 4,702 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.40 · Expires 2034-06-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-11 · Disposition to issuer · Disposed 10,450 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.74 · Expires 2034-01-18 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-11 · Disposition to issuer · Disposed 20,900 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2033-01-26 | Direct | 0 |
Reported balance
After 2025-02-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-11 · Disposition to issuer · Disposed 32,400 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash.
F2: Represents 4,702 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU.
F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 15, 2026 23:48 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 18,160 | $5.71 | $103,695.42 |
DisclosureSEC source: 0001493152-26-028777 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,562 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.73 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 20,070 | $5.09 | $102,168.34 |
DisclosureSEC source: 0001493152-26-005106 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,722 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.12 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 37,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-003807 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,792 F1 · shares: All of the restricted stock will vest on January 26, 2027. Read SEC document |
| July 09, 2025 Filed Jul 10, 2025 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 13,093 | $5.86 | $76,668.68 |
DisclosureSEC source: 0001641172-25-018605 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,479 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.78 to $5.92 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:10 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 32,400 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001104659-25-011238 · tm255946-1_4seq1.xml · derivative · entry 5 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,400 shares Expires 2033-01-26 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:10 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001104659-25-011238 · tm255946-1_4seq1.xml · derivative · entry 4 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,900 shares Expires 2034-01-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:10 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,450 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001104659-25-011238 · tm255946-1_4seq1.xml · derivative · entry 3 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,450 shares Expires 2034-06-18 F3 · kind: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding out-of-the-money stock option (i.e., a stock option that has an exercise price per share that is greater than the Offer Price) was terminated and the Reporting Person was not entitled to any payment in respect thereof. Read SEC document |
| February 11, 2025 Filed Feb 11, 2025 09:10 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 4,702 | $0.55 | $2,586.10 |
DisclosureSEC source: 0001104659-25-011238 · tm255946-1_4seq1.xml · nonDerivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F2 · shares: Represents 4,702 shares underlying Restricted Stock Units (the "RSUs"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time"), each outstanding RSU was terminated in exchange for a lump sum cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of Common Stock underlying the RSU. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| February 07, 2025 Filed Feb 11, 2025 09:10 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | Disposition to issuerCommon Stock | 9,398 | $0.55 | $5,168.90 |
DisclosureSEC source: 0001104659-25-011238 · tm255946-1_4seq1.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,702 F1 · kind: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. F1 · price: On December 29, 2024, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Immedica Pharma AB, a corporation organized and existing under the laws of Sweden ("Parent"), and Matador Subsidiary, Inc. a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the terms of the Merger Agreement and the Offer (as defined in the Merger Agreement), each share of the Issuer's common stock (the "Common Stock") held by the Reporting Person was acquired, subject to adjustment, at a purchase price of $0.55 per share (the "Offer Price") in cash. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:37 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 36,101 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-004752 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,572 F1 · kind: Upon vesting, a portion of the restricted stock may be surrendered to satisfy the reporting person's tax withholding obligation. Any deemed disposition of the withheld shares would be exempt pursuant to Rule 16b-3(e). F2 · shares: All of the restricted stock will vest on January 31, 2026. Read SEC document |
| August 26, 2024 Filed Aug 27, 2024 23:09 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 11,797 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-034056 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,471 F1 · kind: The acquisition was exempt pursuant to Rule 16b-3(d). F2 · shares: This stock grant represents the remainder of the 2024 annual grant to board of directors. This portion of the annual stock grant was withheld until all employees/management were allocated their shares and in order to enable onboarding of two new Board members. All of the restricted stock will vest on August 26, 2025. Read SEC document |
| July 08, 2024 Filed Jul 9, 2024 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 23,611 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026647 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,674 F1 · shares: All of the restricted stock will vest on July 8, 2025. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 25,821 | $4.51 | $116,452.71 |
DisclosureSEC source: 0001493152-24-024527 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,063 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $4.47 to $4.55 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:27 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 10,450 | $0.00 Strike: $1.40 | $0.00 |
DisclosureSEC source: 0001415889-24-017643 · form4-06202024_080629.xml · derivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,450 Underlying: Common Stock · 10,450 shares Expires 2034-06-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in full on July 15, 2025, subject to the reporting person's continued service with the Issuer. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:27 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-017643 · form4-06202024_080629.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,100 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on July 15, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:27 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 20,900 | $0.00 Strike: $9.74 | $0.00 |
DisclosureSEC source: 0001415889-24-001602 · form4-01192024_090103.xml · derivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,900 Underlying: Common Stock · 20,900 shares Expires 2034-01-18 F2 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal monthly installments beginning on February 18, 2024, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 18, 2024 Filed Jan 19, 2024 16:27 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 4,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001602 · form4-01192024_090103.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,800 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs vest in full on January 18, 2025, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 20:30 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | SaleCommon Stock | 6,330 | $3.91 | $24,721.18 |
DisclosureSEC source: 0001493152-23-034858 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,884 F1 · kind: The sale reported in this Form 4 was to cover tax obligations associated with vesting of restricted stock awards. F2 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8200 to $4.2000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 20:05 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 58,689 | $4.62 | $271,143.18 |
DisclosureSEC source: 0001493152-23-021648 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,214 F1 · shares: All of the restricted stock will vest on June 14, 2024. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:15 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantStock Option (Right to Buy) · Derivative | 32,400 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001415889-23-001546 · form4-01302023_090103.xml · derivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,400 Underlying: Common Stock · 32,400 shares Expires 2033-01-26 F2 · derivative.exercise_date: The option vests and becomes exercisable in 36 equal monthly installments beginning on February 26, 2023, subject to the reporting person's continued service with the Issuer. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 16:15 UTC | MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359 | GrantCommon Stock | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-001546 · form4-01302023_090103.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,200 F1 · shares: Represents the grant of restricted stock units (RSUs). The RSUs will vest in three equal annual installments, with the first installment vesting on January 26, 2024, the second installment vesting on January 26, 2025 and the third installment vesting on January 26, 2026, subject to the reporting person's continued service with Marinus Pharmaceuticals, Inc. (the Issuer). Each RSU represents the right to receive one share of common stock of the Issuer. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 20:38 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 13,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-027051 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,525 F1 · shares: All of the restricted stock will vest on September 26, 2023. F2 · balance_after: On July 1, 2022, the issuer effectuated a 1-for-25 reverse stock split. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:45 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 49,084 | $0.00 Strike: $1.49 | $0.00 |
DisclosureSEC source: 0001493152-21-013121 · ownership.xml · derivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,084 Underlying: Common Stock · 49,084 shares Expires 2031-05-25 F2 · derivative.exercise_date: All of the stock options will vest on November 25, 2021. Read SEC document |
| May 25, 2021 Filed May 28, 2021 01:45 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 38,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013121 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,590 F1 · shares: All of the restricted stock will vest on November 25, 2021. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 93,750 | Not disclosed Strike: $2.69 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 14 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,750 shares Expires 2026-05-02 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F7 · derivative.exercise_date: The options vest 25% on May 2, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 93,750 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 13 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,750 Underlying: Common Stock · 93,750 shares Expires 2026-05-02 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F7 · derivative.exercise_date: The options vest 25% on May 2, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $4.45 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 12 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2026-12-13 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F6 · derivative.exercise_date: The options vest 25% on December 13, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 75,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 11 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-12-13 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F6 · derivative.exercise_date: The options vest 25% on December 13, 2017, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 10 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2027-12-14 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F5 · derivative.exercise_date: The options vest 25% on December 14, 2018, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 9 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2027-12-14 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F5 · derivative.exercise_date: The options vest 25% on December 14, 2018, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $7.02 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 8 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-01-07 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F4 · derivative.exercise_date: The options vest 25% on January 7, 2020, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 7 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-07 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F4 · derivative.exercise_date: The options vest 25% on January 7, 2020, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 80,000 | Not disclosed Strike: $7.24 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 6 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2029-04-09 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F3 · derivative.exercise_date: The options vest 25% on April 9, 2020, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 80,000 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 5 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-04-09 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F3 · derivative.exercise_date: The options vest 25% on April 9, 2020, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 102,163 | Not disclosed Strike: $1.45 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 4 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 102,163 shares Expires 2030-03-16 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 102,163 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 3 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,163 Underlying: Common Stock · 102,163 shares Expires 2030-03-16 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | Disposition to issuerStock Option (right to buy) · Derivative | 57,837 | Not disclosed Strike: $3.20 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,837 shares Expires 2030-03-16 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| November 20, 2020 Filed Nov 20, 2020 23:00 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantStock Option (right to buy) · Derivative | 57,837 | Not disclosed Strike: $1.28 | Not disclosed |
DisclosureSEC source: 0001493152-20-022149 · ownership.xml · derivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,837 Underlying: Common Stock · 57,837 shares Expires 2030-03-16 F2 · price: The options granted on May 20, 2020, March 16, 2020, April 9, 2019, January 7, 2019, December 14, 2017, December 13, 2016 and May 2, 2016 have each been modified to reflect a lower exercise price. F1 · derivative.exercise_date: The options vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:17 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantEmployee Stock Option (right to buy) · Derivative | 57,837 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001493152-20-009766 · ownership.xml · derivative · entry 2 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,837 Underlying: Common Stock · 57,837 shares Expires 2030-05-20 F2 · derivative.exercise_date: The stock options will vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| May 20, 2020 Filed May 22, 2020 22:17 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantCommon Stock | 80,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-009766 · ownership.xml · nonDerivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · shares: The restricted stock will vest 25% on March 31, 2021, and in three equal annual installments thereafter. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:35 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantEmployee Stock Option (right to buy) · Derivative | 102,163 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001493152-20-004254 · ownership.xml · derivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,163 Underlying: Common Stock · 102,163 shares Expires 2030-03-16 F2 · security: Contingent upon stockholder approval of an amendment to the 2015 Equity Incentive Plan (the "2015 Plan") at the Annual Meeting of Stockholders scheduled for May 20, 2020 to increase the number of shares available under the 2015 Plan, Ms. Silverstein will also be entitled to an additional grant of 57,837 stock options and a grant of 80,000 shares of restricted stock as soon as practicable after the amendment of the 2015 Plan. The stock options contingent upon stockholder approval will have an exercise price determined at the grant date. F1 · derivative.exercise_date: The options will vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter. Read SEC document |
| April 09, 2019 Filed Apr 11, 2019 22:52 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantEmployee Stock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0001144204-19-019348 · tv518743_4.xml · derivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-04-09 F1 · derivative.exercise_date: The options will vest 25% on April 9, 2020, and in 36 equal monthly installments thereafter. Read SEC document |
| January 07, 2019 Filed Apr 18, 2019 21:58 UTC | ABEONA THERAPEUTICS INC. ABEO · Entity 5808 | GrantEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001144204-19-020316 · tv519201_4.xml · derivative · entry 1 Silverstein Christine Berni · CIK 0001772546 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-07 F1 · derivative.exercise_date: The options will vest 25% on January 7, 2020, and in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.